The lncRNA ELDR suppresses tumorigenicity of AML by interfering with DNA replication and chromatin accessibility
Open Access
- 2 December 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (23) , 6158-6174
Abstract
Acute myeloid leukemia (AML) with rearrangement of the mixed lineage leukemia gene expresses MLL-AF9 fusion protein, a transcription factor that impairs differentiation and drives expansion of leukemic cells. In this work, the zinc finger protein “growth factor independent 1” together with the histone methyltransferase LSD1 is revealed to occupy the promoter and regulate the expression of the lncRNA ELDR (EGFR [epidermal growth factor receptor] long non-coding downstream RNA) in the rearranged Mixed Lineage Leukemia (MLL) (MLL-r) AML cell line THP-1. Forced ELDR overexpression enhanced the growth inhibition of an Lysine-Specific Demethylase 1 inhibitor (LSD1i)/all-trans retinoic acid (ATRA) combination treatment and reduced the capacity of these cells to generate leukemia in xenografts, leading to a longer leukemia-free survival. ELDR is found to bind the clamp protein Proliferating Cell Nuclear Antigen (PCNA) and the MCM5 helicases causing defects of DNA replication fork progression. Moreover, AML cells overexpressing ELDR had reduced chromatin accessibility and transcription at α-satellite repeats in centromeres. In addition, ELDR RNA was detected close to MLL-AF9 at centromeres suggesting that it impedes leukemic progression preferentially of MLL-r AML by interfering with both DNA replication and centromeric transcription. Our findings reveal novel functions of the lncRNA ELDR in DNA replication and centromere biology when expressed at high levels in AML cells with MLL rearrangements. These discoveries could provide rationale for future strategies to treat MLL-r AML, which has a poor prognosis in children and adults. Delivery of the ELDR RNA could potentially be used as an adjunct to LSD1i/ATRA treatment or other currently used chemotherapeutic drugs to develop novel therapies for these AML subtypes.Keywords
This publication has 49 references indexed in Scilit:
- Dynamic chromatin accessibility tuning by the long noncoding RNA ELDR accelerates chondrocyte senescence and osteoarthritisThe American Journal of Human Genetics, 2023
- Targeting LSD1 for acute myeloid leukemia (AML) treatmentPharmacological Research, 2021
- The transcription factors GFI1 and GFI1B as modulators of the innate and acquired immune response2021
- Alpha satellite DNA biology: finding function in the recesses of the genomeChromosome Research, 2018
- Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid LeukemiaCell Reports, 2018
- Systematic Discovery of Xist RNA Binding ProteinsCell, 2015
- ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐WideCurrent Protocols in Molecular Biology, 2015
- The Nucleoplasmin Homolog NLP Mediates Centromere Clustering and Anchoring to the NucleolusMolecular Cell, 2013
- Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11Cell, 2011
- Centromere-Specific Assembly of CENP-A Nucleosomes Is Mediated by HJURPCell, 2009